Neumora Therapeutics, Inc. (NMRA) - Form 8-K Summary
Business Context and Reporting Period
Neumora Therapeutics, Inc., a Delaware corporation, filed this Current Report on Form 8-K on March 30, 2026. The filing announces the financial results for the fourth quarter and full year ended December 31, 2025. The company's common stock trades on The Nasdaq Global Select Market under the symbol NMRA.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notification that these results have been announced and directs readers to the attached press release (Exhibit 99.1) for the full details.
Material Changes
No material changes versus the prior comparable period are detailed within the text of this Form 8-K. Specific comparative data is contained in the referenced press release.
Guidance, Outlook, and Risks
The filing does not contain specific guidance, outlook, management commentary, or risk factors. It explicitly states that the information furnished, including the attached press release, is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 30, 2026) for specific Q4 and full-year 2025 financial figures.
- Verify the company's cash position and burn rate in the detailed financial statements referenced in the press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the full press release.
- Confirm the status of the company's emerging growth company election, as indicated by the unchecked box in the filing.